Asia Pacific Hospital-Acquired Infection Diagnostics Market Size, 2028

Asia Pacific Hospital-Acquired Infection Diagnostics Market Size, Share & Industry Trends Analysis Report By Product (Reagents & Consumables and Instrument), By Infection Type, By Application, By Test Type, By End User, By Country and Growth Forecast, 2022 - 2028

Published Date: May-2022 | Number of Pages: 125 | Format: PDF | Report ID: KBV-18231

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


COVID-19

Get in-depth analysis of the COVID-19 impact on the Asia Pacific Hospital-Acquired Infection Diagnostics Market

Market Report Description

The Asia Pacific Hospital-Acquired Infection Diagnostics Market would witness market growth of 8.5% CAGR during the forecast period (2022-2028).

Obtaining detailed information about the patient's medical history and completing a comprehensive physical examination is critical in evaluating whether the infection occurred before admission or was acquired in the hospital. Important details from the past, such as subjective temperature, chills, and night sweats, could imply that the infection was not caught in the hospital. Fever, altered mental status, chills, shortness of breath, productive cough, palpitations, abdominal discomfort, flank pain, polyuria, dysuria, suprapubic pain, and diarrhea are all common infection symptoms. Vital signs can reveal symptoms of sepsis or a systemic inflammatory reaction. Hypothermia or hyperthermia, tachycardia, tachypnea, and hypotension are examples. Tracheostomies, foley catheters, endotracheal tubes, intravascular lines, insulin pumps, and pacemakers/defibrillators must all be thoroughly examined. The information about the device's position and placement complement the evaluation of external devices (setting and duration).

Asia Pacific region is one of the regions that has been recording the patients that acquired the infections from the hospital itself and eventually get permanently disabled or sometimes die. Hospital-acquired infections (HAIs) pose a significant threat to patient safety and have significant public health implications, as it affect patients' quality of life and can sometimes result in death or permanent disability. The full cost of HAI, particularly in developing nations, is unknown.

As the government battles a recurrence of locally transmitted cases, China has stepped up measures to avoid infections in hospitals. For instance, according to a directive established by the State Council interagency working force for COVID-19 response, hospitals authorized for treating complicated cases should take aggressive measures to contain infections. All hospital-acquired infection cases, both locally and imported contracted, along with asymptomatic carriers, were admitted to recognized hospitals' isolation wards and kept segregated from patients with other kinds of diseases.

The China market dominated the Asia Pacific Hospital-Acquired Infection Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $463.6 million by 2028. The Japan market is poised to grow at a CAGR of 7.9% during (2022 - 2028). Additionally, The India market would display a CAGR of 9.2% during (2022 - 2028).

Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Hospital-Acquired Infection Diagnostics Market is Projected to reach USD 5.6 Billion by 2028, at a CAGR of 7.8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.

Scope of the Study

Market Segments Covered in the Report:

By Product

  • Reagents & Consumables
  • Instrument

By Infection Type

  • Urinary Tract Infections (UTI)
  • Hospital Acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Others

By Application

  • Drug-Resistance Testing
  • Disease Testing

By Test Type

  • Molecular Diagnostics
  • Immunoassay
  • Urinalysis

By End User

  • Hospital
  • Standalone Laboratories
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Bayer AG (Bayer Schering Pharma AG)
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Ecolab, Inc.
  • Pfizer, Inc.
  • Steris PLC
  • Johnson & Johnson
  • Abbott Laboratories
  • Merck Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global Hospital-Acquired Infection Diagnostics Market Report 2022-2028

North America Hospital-Acquired Infection Diagnostics Market Report 2022-2028

Europe Hospital-Acquired Infection Diagnostics Market Report 2022-2028

LAMEA Hospital-Acquired Infection Diagnostics Market Report 2022-2028

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities